HMDB ID | Metabolite name | Reference | Chromatography | Ion source | Specimen | Marker function | Participants (Case) | Participants (Control) | Fold change | P-value | FDR | VIP | |||
Cancer type | Stage | Number | Type | Number |
HMDB ID | Metabolite name | Reference | Chromatography | Ion source | Specimen | Marker function | Participants (Case) | Participants (Control) | Fold change | P-value | FDR | VIP | |||
Cancer type | Stage | Number | Type | Number | |||||||||||
HMDB0000001 | 1-methylhistidine | Yue et al. 2018 | LC | ESI | plasma | diagnosis | SCLC | – | 20 | healthy | 20 | 2.69 | 4.35e-04 | – | 1.27 |
HMDB0000001 | 1-methylhistidine | Klupczynska et al. 2016a | LC | – | serum | diagnosis | adenocarcinoma, squamous cell carcinoma | I, II, III | 90 | healthy | 63 | 0.85 | 0.76 | – | – |
HMDB0000001 | 1-methylhistidine | Moreno et al. 2018 | LC, GC | ESI, EI | tissue | therapy, diagnosis | squamous cell carcinoma | I, II, III | 35 | tumor vs. adjacent normal tissue | 35 | 2.37 | 4.99e-09 | 1.99e-08 | – |
HMDB0000001 | 1-methylhistidine | Qi et al. 2021 | LC | ESI | blood | diagnosis | adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types | I, II, III, IV | 98 | healthy | 75 | 0.65 | 0.03 | – | 1.04 |
HMDB0000008 | 2-hydroxybutanoic acid | Miyamoto et al. 2015 | GC | EI | blood | diagnosis | adenocarcinoma | unknown (mostly late stage) | 18 | healthy | 20 | 1.09 | 0.39 | – | – |
HMDB0000008 | 2-hydroxybutanoic acid | Miyamoto et al. 2015 | GC | EI | blood | diagnosis | NSCLC, SCLC, mesothelioma, secondary metastasis to lung | I, II, III, IV | 11 | healthy | 11 | 1.21 | 0.19 | – | – |
HMDB0000008 | 2-hydroxybutanoic acid | Fahrmann et al. 2015 | GC | EI | plasma | diagnosis | adenocarcinoma | I, II, III, IV | 52 | healthy | 31 | 1.13 | 0.22 | 0.59 | – |
HMDB0000008 | 2-hydroxybutanoic acid | Fahrmann et al. 2015 | GC | EI | serum | diagnosis | adenocarcinoma | I, II, III, IV | 43 | healthy | 43 | 1.31 | 6.00e-03 | 0.07 | – |
HMDB0000008 | 2-hydroxybutanoic acid | Fahrmann et al. 2015 | GC | EI | serum | diagnosis | adenocarcinoma | I, II, III, IV | 49 | healthy | 31 | 1.13 | 0.29 | 0.62 | – |
HMDB0000008 | 2-hydroxybutanoic acid | Fahrmann et al. 2015 | GC | EI | plasma | diagnosis | adenocarcinoma | I, II, III, IV | 43 | healthy | 43 | 1.21 | 0.08 | 0.26 | – |